$150m Californian stem cell hand-out includes support for StemCells' spinal programme
This article was originally published in Clinica
Executive Summary
The California Institute for Regenerative Medicine (CIRM) governing board has approved a $20m loan for StemCells Inc's neural stem cell transplantation for chronic cervical spinal cord injury program. It also awarded $130m in grants to seven multidisciplinary teams of academic scientists and hospital researchers preparing to advance their projects into clinical trials.
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.